Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MEDIA STATEMENT - Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide...

NVS : 103.85 (+0.74%)
Top Stock Reports for Netflix, Salesforce & Cisco

Tuesday, November 12, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc....

NFLX : 896.44 (+1.42%)
CSCO : 57.56 (+0.10%)
TSLA : 339.64 (-0.70%)
TTE : 60.01 (-0.84%)
NVS : 103.85 (+0.74%)
CRM : 335.20 (+2.92%)
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...

BAYRY : 5.0850 (-1.07%)
NVS : 103.85 (+0.74%)
REGN : 744.25 (+0.12%)
SNY : 47.97 (+0.40%)
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript

NVS earnings call for the period ending September 30, 2024.

NVS : 103.85 (+0.74%)
3 Absurdly Cheap Stocks That Pay High Dividends

These stocks are trading at less than 15 times their expected future profits.

MRK : 100.09 (+2.72%)
NVS : 103.85 (+0.74%)
GILD : 89.75 (+1.26%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

For Immediate ReleaseChicago, IL – October 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 102.57 (-2.56%)
NVS : 103.85 (+0.74%)
REGN : 744.25 (+0.12%)
PFE : 25.06 (+0.48%)
BIIB : 157.92 (+1.23%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

For Immediate ReleaseChicago, IL – October 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 102.57 (-2.56%)
NVS : 103.85 (+0.74%)
REGN : 744.25 (+0.12%)
PFE : 25.06 (+0.48%)
BIIB : 157.92 (+1.23%)
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently...

NVO : 102.57 (-2.56%)
NVS : 103.85 (+0.74%)
REGN : 744.25 (+0.12%)
PFE : 25.06 (+0.48%)
BIIB : 157.92 (+1.23%)
Novartis Gets CHMP Recommendation for Kisqali in Broader Population

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...

BAYRY : 5.0850 (-1.07%)
LLY : 748.15 (-0.70%)
NVS : 103.85 (+0.74%)
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Novartis is taking a more calculated and strategic approach to its growth.

NVS : 103.85 (+0.74%)

Barchart Exclusives

Recent Corn Rally Artificially Propped Up – What’s Next?
Corn prices appeared to have finally found a bottom from the summer sell-off. Speculators were short the market in record numbers until late August, when they began buying back contracts, convincing some that the harvest seasonal low may be in. Then, exports increased in the last few weeks, and prices rallied more. While the bearish fundamentals of 1.9 billion carry-out and the massive amount of unpriced corn still linger, there isn’t much hope for a significant price rally yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar